B lymphocytes and other immune cell receptors

B lymphocytes and other immune cell receptors represent a broad class of membrane-bound proteins that facilitate antigen recognition and immune signaling. These receptors, such as the B-cell receptor (BCR) and various Cluster of Differentiation (CD) markers like CD19, CD20, and CD22, are essential for the development, maturation, and activation of B cells (Janeway's Immunobiology, 2001). They play a fundamental role in the adaptive immune response by initiating signal transduction pathways that lead to cell proliferation and the production of antibodies (Nature Reviews Immunology, 2020). In disease states, these receptors are often involved in the pathogenesis of B-cell malignancies and autoimmune disorders, where they may be overexpressed or dysregulated (NCBI, 2022). Therapeutic targeting of these receptors is a cornerstone of modern immunotherapy, utilizing monoclonal antibodies like Rituximab to induce cell death via ADCC or CDC (StatPearls, 2023). Additionally, newer modalities like CAR-T cell therapies specifically target receptors like CD19 to treat refractory leukemias and lymphomas (NIH, 2023). Because this term refers to a heterogeneous group of molecules rather than a single protein, it serves as a functional category for various distinct therapeutic targets. Monitoring these receptors as biomarkers is crucial for patient stratification and assessing the efficacy of B-cell depleting therapies. Safety considerations for drugs hitting these targets often involve the risk of severe immunosuppression and infusion-related toxicities (FDA, 2023).

Other names

B-cell surface antigensLymphocyte receptorsImmune cell markersBCR complexB-cell surface receptors

Drugs targeting these receptors typically act through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct induction of apoptosis to deplete specific immune cell populations (StatPearls, 2023). Additionally, bispecific antibodies and CAR-T cell therapies engage these receptors to redirect T-cell toxicity against malignant B cells (NIH, 2023).